F2G’s Olorofim Receives the US FDA’s Breakthrough Therapy Designation to Treat Invasive Mold Infections in Patients with Limited or No Treatment Options

Shots:

• The BT designation follows the P-IIb Trial in patients with IFD or probable invasive aspergillosis (IA) and either refractory disease, resistance, or intolerance to available agents
• The study resulted in well tolerable results across more than 10 years of patient dosing days with a median therapy duration of 12 wks.
• Olorofim is first antifungal agent targeted to treat invasive fungal mold infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and other rare mold infections and is being developed as IV and oral formulation

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: F2G